Stock Markets Analysis & Opinion

Good day traders!S&P 500 is trading in its final stages of a bullish impulse, and can see limited upside near the 2752/2760 region, where Fibonacci projection of 161.8 and 261.8 sit. On that note...

MyBucks SA (DE:MBCG) is pursuing technological and regional growth initiatives despite immediate challenges in integrating new acquisitions. The group is fully committed to its strategy of supplying...

The DAX has posted slight gains in the Tuesday session. Currently, the index is at 13,380.00, up 0.10% on the day. On the release front, German Industrial Production rebounded with a sharp gain of...

Ford (NYSE:F) took to the International Consumer Electronics Show stage in Las Vegas on Tuesday and has taken an early lead at this year’s showcase—in terms of tech that aims to reshape...

Though utility companies are among the safest investment bets, they have their share of weaknesses. Regulatory burdens, weather variation and increased debt loads are major concerns. While the Trump...

Indian stocks are rallying to record highs despite rising crude prices and slowing GDP growth. Investors are optimistic about quarterly earnings and government’s fiscal budget in February....

Caterpillar Inc. (NYSE:CAT) touched an all-time high of $166.43 on Jan 8, before settling a tad lower at $166.03, but logging a jump of 3% in the day. The rise was triggered by an upgrade from JP...

Acuity Brands, Inc.’s (NYSE:AYI) reported first-quarter fiscal 2017 adjusted earnings of $1.94 per share, missing the Zacks Consensus Estimate of $2.10 by 7.6%. Earnings were down 3% on a year...

Emergent BioSolutions Inc. (NYSE:EBS) provided preliminary results for 2017 and its guidance for 2018. While the results exceeded management’s guidance issued in November 2017, the...

The restaurant industry exhibited a moderate growth rate in 2017. Per the National Restaurant Association (NRA), the industry is expected to have generated $799 billion in revenues in the year, up...

AbbVie (NYSE:ABBV) announced that the FDA has granted Breakthrough Therapy Designation (“BTD”) to its investigational JAK1 inhibitor, upadacitinib (ABT-494) for the treatment of severe...

Acorda Therapeutics, Inc. (NASDAQ:ACOR) announced preliminary sales numbers of its key multiple sclerosis drug, Ampyra, for the fourth quarter of 2017 and issued a financial outlook for 2018 at the...

Teladoc Inc. (NYSE:TDOC) posted impressive preliminary fourth-quarter and full-year 2017 results.Fourth-quarter revenues of $76 million were up 103% year over year and were higher than the guidance...

The Retail-Wholesale sector is hogging all the attention, and this time for good reasons. For the time being, the expression "retail apocalypse” appears to be a thing of past. The sector has...